Cardiac hypertrophy: mechanisms and therapeutic opportunities
- PMID: 17511580
- DOI: 10.1089/ars.2007.1474
Cardiac hypertrophy: mechanisms and therapeutic opportunities
Abstract
Cardiac hypertrophy and heart failure are major causes of morbidity and mortality in Western societies. Many factors have been implicated in cardiac remodeling, including alterations in gene expression in myocytes, cardiomyocytes apoptosis, cytokines and growth factors that influence cardiac dynamics, and deficits in energy metabolism as well as alterations in cardiac extracellular matrix composition. Many therapeutic means have been shown to prevent or reverse cardiac hypertrophy. New concepts for characterizing the pathophysiology of cardiac hypertrophy have been drawn from various aspects, including medical therapy and gene therapy, or use of stem cells for tissue regeneration. In this review, we focus on various types of cardiac hypertrophy, defining the causes of hypertrophy, describing available animal models of hypertrophy, discussing the mechanisms for development of hypertrophy and its transition to heart failure, and presenting the potential use of novel promising therapeutic strategies derived from new advances in basic scientific research.
Similar articles
-
Mechanisms of physiological and pathological cardiac hypertrophy.Nat Rev Cardiol. 2018 Jul;15(7):387-407. doi: 10.1038/s41569-018-0007-y. Nat Rev Cardiol. 2018. PMID: 29674714 Review.
-
Overexpression of microRNA-99a Attenuates Cardiac Hypertrophy.PLoS One. 2016 Feb 25;11(2):e0148480. doi: 10.1371/journal.pone.0148480. eCollection 2016. PLoS One. 2016. PMID: 26914935 Free PMC article.
-
Exosomes as New Intercellular Mediators in Development and Therapeutics of Cardiomyocyte Hypertrophy.Adv Exp Med Biol. 2017;998:91-100. doi: 10.1007/978-981-10-4397-0_6. Adv Exp Med Biol. 2017. PMID: 28936734 Review.
-
Bone marrow mesenchymal stem cell-derived exosomes attenuate cardiac hypertrophy and fibrosis in pressure overload induced remodeling.In Vitro Cell Dev Biol Anim. 2020 Aug;56(7):567-576. doi: 10.1007/s11626-020-00481-2. Epub 2020 Aug 3. In Vitro Cell Dev Biol Anim. 2020. PMID: 32748023
-
Molecular switches under TGFβ signalling during progression from cardiac hypertrophy to heart failure.Br J Pharmacol. 2016 Jan;173(1):3-14. doi: 10.1111/bph.13344. Epub 2015 Nov 16. Br J Pharmacol. 2016. PMID: 26431212 Free PMC article. Review.
Cited by
-
Over-expression of a cardiac-specific human dopamine D5 receptor mutation in mice causes a dilated cardiomyopathy through ROS over-generation by NADPH oxidase activation and Nrf2 degradation.Redox Biol. 2018 Oct;19:134-146. doi: 10.1016/j.redox.2018.07.008. Epub 2018 Jul 17. Redox Biol. 2018. PMID: 30153650 Free PMC article.
-
Mechanical regulation of gene expression in cardiac myocytes and fibroblasts.Nat Rev Cardiol. 2019 Jun;16(6):361-378. doi: 10.1038/s41569-019-0155-8. Nat Rev Cardiol. 2019. PMID: 30683889 Free PMC article. Review.
-
Animal models of cardiac disease and stem cell therapy.Open Cardiovasc Med J. 2010 Nov 26;4:231-9. doi: 10.2174/1874192401004010231. Open Cardiovasc Med J. 2010. PMID: 21258568 Free PMC article.
-
Myocardial infarction-induced microRNA-enriched exosomes contribute to cardiac Nrf2 dysregulation in chronic heart failure.Am J Physiol Heart Circ Physiol. 2018 May 1;314(5):H928-H939. doi: 10.1152/ajpheart.00602.2017. Epub 2018 Jan 26. Am J Physiol Heart Circ Physiol. 2018. PMID: 29373037 Free PMC article.
-
Different effects of prolonged β-adrenergic stimulation on heart and cerebral artery.Integr Med Res. 2014 Dec;3(4):204-210. doi: 10.1016/j.imr.2014.10.002. Epub 2014 Oct 13. Integr Med Res. 2014. PMID: 28664099 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources